Recombinant vaccine has become a new step in medicine and vaccination. Currently, this type of vaccination is most widely used, effectively preventing hepatitis B. Consider the general features of drugs of this class, their key differences. Pay attention to the most famous products.
general information
The manufacture of a recombinant vaccine involves first cloning the genetic material to generate antigen, then introducing the obtained raw materials into the vector, introducing the vector into the producers. The next step is laboratory cultivation, after which the antigen is isolated and purified. An alternative is the use of producers as an element of the vaccine.
The prepared product must first be studied. To do this, use a reference drug that has successfully passed preclinical level checks and at the clinical step. Differences in different series indicate unstable vectors and the loss of cellular material in the process. At the final stage of the work, you need to check how large the percentage of cells including the vector is. Strict requirements are formulated for the virus vector. Attenuation should be high, while oncogenic activity is unacceptable. It is unacceptable to use material that provokes additional undesirable effects.
Preparations of the future?
According to scientists, recombinant vaccines are completely safe. Such funds show a high degree of effectiveness. The production process of such a pharmaceutical product involves the use of the most effective and modern methods and technologies. Finished products are used to create complex preparations for vaccinating the population. Their use allows people to form immunity against several pathogens at the same time.
About famous products: “Bubo-Kok”
The Bubo-Kok vaccine is produced in the form of a suspension intended for injective administration into muscle tissue. The tool is not used with increased susceptibility by the body, progressive nervous pathologies, severe complications that previously appeared on the background of vaccination. You can not use the drug if the patient previously suffered afebrile convulsions. The vaccine is not administered in the acute phase of the disease, during the relapse of chronic pathology. In such conditions, vaccination is delayed until the needy is cured.
The Bubo-Kok vaccine is administered in the muscle, in the buttock. An outer quadrant must be used. It is allowed to enter the anterior lateral femoral surface. A single dosage is half a milliliter. The vaccine is given based on the national vaccination calendar. If a child under three months of age has not received the hepatitis B vaccine, it is necessary to administer Bubo-Kok three times. Initially, an injection is made at the age of three months, then they are repeated twice with one and a half month pauses.
Application features
If the use of the Bubo-Kok recombinant vaccine is intended, it is strictly forbidden to shorten the pauses between administrations. Sometimes there is a need to increase the waiting intervals. In this case, the drug is administered immediately, as soon as children's health allows injection. If you have previously been given once or twice injections of DTP, while you have not received funds to prevent hepatitis B, you need to do an additional injection of monovaccine. They use the Bubo-Kok medicine to complete the vaccination course, which should include receiving prophylactic drugs three times.
Re-vaccination is carried out by the administration of DTP once at 18 months of age. If the standard terms are violated, a second injection is prescribed 12-13 months after the first course. If a repeated vaccine has not yet been received by the age of four, an toxoid ADS for children under six years of age or ADS-M for older persons is used for administration.
Activity Features
If you ask the doctor what “recombinant vaccine” means, how it works, the doctor will answer that it is a specially manufactured pharmaceutical product designed to prevent serious illnesses. The manufacturing feature is described above. The pharmacology of the drug is such that a person has a specific immunity that prevents tetanus disease, eliminating whooping cough, diphtheria and hepatitis B.
The use of such a drug is associated with certain risks. Recombinant vaccination can cause short-term systemic, local reactions. The temperature may rise, the general condition of the child is weak, the area of administration responds with pain and is hot to the touch. There is a possibility of local edema. Usually this appears in the first two days after administration. Rarely, an injection leads to cramps, allergies, and crying episodes.
"Recombinant Yeast Vaccine"
Such a product is manufactured by the domestic pharmaceutical company Kombiotekh. It has the chemical formula of a protein sorbed by aluminum molecules produced by a recombinant yeast strain. The composition contains antigen determinants, which provides protection against hepatitis B. The vaccine includes 20 μg of protein, half a milligram of aluminum compound. Perhaps the inclusion of a preservative ingredient - merthiolate. If there is one, it is used in an amount of 50 mcg. You can clarify the presence of a preservative in the instructions that accompany the specific release.
The vaccine is intended for administration to muscle tissue. You can not use the drug in the acute course of the disease, fever, sensitization reactions to the ingredients of the product. Do not use the product for allergies to products containing yeast. A similar list of contraindications is inherent in the Bubo M vaccine, which is considered a reliable analogue of the yeast recombinant.
Application features
The introduction of a yeast vaccine can trigger an increase in overall body temperature. Some have a headache. The baby may feel sick. The injection site sometimes bothers with pain, it becomes somewhat denser. The product is intended for children and adults. With the introduction, you need to be guided by the national vaccination calendar and the instructions for the drug.
The list of recombinant vaccines, in addition to those described, also includes rDNA. This is a recombinant product designed to prevent hepatitis B. In the same list you can see the pharmaceutical development of Angerix B, Eberbiovac. The product “Euvax B”, which belongs to the class of preventive injections under consideration, is well-known.
Regevak B
This product is also recombinant, as indicated in the accompanying instructions for use. "Regevac B" is made in the form of a white liquid, slightly turning into gray. There should be no inclusions visible to the eye. One dose is half a milliliter. It contains 10 micrograms of the virus and buffer ingredients, 25 micrograms of preservative and aluminum sorbent. Preservative component may be absent. To clarify its presence, you need to study the document that accompanies a particular ampoule. Children's dose - 0.5 mg. For adults put twice as much volume.
Pharmacology
Regevac B is a pharmaceutical product designed to prevent cases of hepatitis B. The product contains a viral antigen that has undergone special purification. The product is made recombinantly using yeast culture. The vaccine administration program allows the formation of specific antigens in humans. A protective titer is achievable on average in 90% of those who received the vaccine.
Medication is used when it is necessary to administer vaccine injections according to the national calendar. The drug is indicated for those who come into contact with hepatitis B-infected material, as well as all health workers who work with blood. It is necessary to give a vaccine to people working in the field of the production of immunobiological products from human blood.
Cases and Practices
The manufacturer of the Regevac B vaccine recommends administering this drug to people who are at particular risk of hepatitis B. They are people of any age living in the same house as the carrier of the virus or someone who is chronically ill with hepatitis. The high-risk category includes residents of orphanages, boarding schools, as well as people who are constantly receiving blood products, directly blood. The same risks are inherent in patients with malignant blood disease and people who are forced to undergo hemodialysis.
Vaccination is recommended for students studying in a medical educational institution of an average, higher level. This is especially true for graduates. Vaccination is prescribed for those who inject drugs for themselves.
Application features
“Regevac B” is allowed to be administered to the child on the first day, then after a month of life, followed by another month and at the age of one, if the mother has been diagnosed with hepatitis B or is diagnosed with such a disease. If a person has not previously been vaccinated, has been in contact with infected biomaterial, it is necessary to administer the drug first, then a month or two after the first injection.
It is allowed to administer “Regevac B” and drugs prescribed on the national calendar in one day. In this case, use different syringes. Medicines are administered in different parts of the body of the needy.